AXON 10-K Annual Reports

Axon Enterprise, Inc. reported strong revenue growth in the fiscal year ending December 31, 2025, with net sales increasing by 33.5% to $2.8 billion. This growth was driven by robust performance in both the Connected Devices segment (up 29.1%) and the Software and Services segment (up 39.6%). Despite the top-line growth, the company experienced a loss from operations of $62.1 million in 2025, a decrease from the $58.5 million income from operations in the prior year. This shift was largely attributed to a significant increase in operating expenses, primarily due to higher headcount to support growth and increased stock-based compensation expenses. Financially, Axon bolstered its liquidity position, ending the year with $1.2 billion in cash and cash equivalents, a substantial increase driven by proceeds from debt and equity offerings. The company also completed several strategic acquisitions, including Prepared and Dedrone, further strengthening its product ecosystem. However, a material weakness in internal control over financial reporting related to revenue recognition was identified, though remediation efforts are underway. Investors should note the company's ongoing investment in research and development, which represents a significant portion of operating expenses, reflecting a commitment to innovation.

Axon Enterprise, Inc. reported strong revenue growth of 33.4% to $2.1 billion for the year ended December 31, 2024. This growth was driven by significant increases in both the TASER segment and the Software and Sensors segment, with notable contributions from TASER device and cartridge sales, as well as Axon Evidence and cloud services. Despite the revenue increase, the company's income from operations decreased to $58.5 million from $156.9 million in the prior year, primarily due to a substantial rise in operating expenses, particularly stock-based compensation and professional/consulting fees related to acquisitions. The company also disclosed two material weaknesses in its internal controls over financial reporting: one related to revenue recognition and another concerning the balance sheet presentation of its convertible senior notes. These weaknesses have led to restatements of prior financial periods. Axon continues to invest heavily in research and development, with R&D expenses increasing by 45.4% year-over-year. The company ended the year with a strong liquidity position, although cash and cash equivalents decreased due to acquisition activities.

Axon Enterprise, Inc. (AXON) reported a strong year of revenue growth, with net sales reaching $2.1 billion, a 33.4% increase compared to the prior year. This growth was driven by robust demand across both its TASER and Software and Sensors segments, with particular strength in TASER devices (especially the new TASER 10) and Axon Evidence cloud services. The company experienced a significant increase in stock-based compensation expenses, which impacted gross margins, but adjusted gross margins improved due to a higher mix of high-margin cloud services and cost-optimization initiatives. Despite a notable increase in operating expenses, primarily related to salaries, benefits, and stock-based compensation, Axon reported a substantial net income of $377.0 million, bolstered by gains on strategic investments. The company also announced a planned reorganization of its reporting segments into "Connected Devices" and "Software & Services" to better reflect its evolving business structure. However, the report disclosed a material weakness in internal controls related to revenue recognition, which management is actively addressing. From an investor perspective, the continued strong top-line growth is a positive indicator, showcasing the sustained demand for Axon's integrated public safety solutions. The strategic acquisitions of Fusus and Dedrone in 2024 demonstrate the company's commitment to expanding its ecosystem and technological capabilities. Investors should monitor the progress of the material weakness remediation and the impact of increasing stock-based compensation on profitability. The company's robust cash flow from operations and significant cash and investment balances provide a solid foundation for future growth and strategic investments, while the ongoing expansion into international markets presents further growth opportunities.

Axon Enterprise, Inc. reported strong revenue growth of 31.4% for the year ended December 31, 2023, reaching $1.6 billion. This growth was driven by both the TASER segment (up 15.2%) and the Software and Sensors segment (up 44.4%), with significant contributions from new product introductions like TASER 10 and Axon Body 4. The company's financial strategy emphasizes highly recurring, profitable businesses, reflected in the robust growth of its Axon Evidence cloud services, which saw a 52.2% increase in revenue. The company's commitment to innovation and strategic growth is evident in its continued investment in R&D, which increased by 29.9% year-over-year. Despite increased operating expenses, particularly in salaries and stock-based compensation, Axon demonstrated improved profitability, with income from operations increasing by 66.0% to $154.8 million. The company also highlighted substantial future contracted revenue of $7.1 billion as of year-end 2023, indicating a strong revenue visibility for the coming years.

Axon Enterprise, Inc. (Axon) reported a strong financial year ended December 31, 2022, with net sales increasing by 37.8% to $1.19 billion. The company successfully transitioned to profitability, reporting a net income of $147.1 million, a significant improvement from a net loss of $60.0 million in the prior year. This turnaround was driven by robust growth across both its TASER and Software and Sensors segments, with notable increases in TASER 7 device sales and Axon Evidence cloud services revenue. The company's strategic focus on recurring revenue models and integrated hardware/software solutions continues to yield positive results, evidenced by a substantial increase in its overall backlog to $4.6 billion. Despite the strong top-line growth and improved profitability, investors should be aware of the identified material weakness in internal controls over financial reporting related to the quote-to-cash cycle, which management is actively working to remediate. Furthermore, the company carries a significant amount of convertible debt, which could lead to dilution if converted. Axon's forward-looking statements highlight a commitment to innovation and market expansion, but also acknowledge risks associated with supply chain, competition, and evolving regulations, particularly concerning its TASER 10 product, which is now regulated as a firearm.

Axon Enterprise, Inc. (AXON) reported strong revenue growth of 26.8% in fiscal year 2021, reaching $863.4 million. This growth was driven by both its TASER segment (up 19.2%) and its Software and Sensors segment (up 35.6%), with the latter showing particularly robust expansion in cloud services and evidence management solutions. Despite revenue growth, the company reported a net loss of $60.0 million for the year, primarily due to a significant increase in stock-based compensation expenses related to its CEO Performance Award and eXponential Stock Performance Plan (XSPP), alongside increased operating expenses from headcount growth and R&D investments. The company anticipates continued growth, projecting revenue of approximately $1 billion for fiscal year 2022 and is making substantial investments in its manufacturing facilities. Key areas of investment include a new manufacturing and office campus in Scottsdale, Arizona, and capacity expansion for TASER devices. Management is focused on its strategic goal of building highly recurring, highly profitable businesses and expanding its total addressable market through new products, customer segments, and geographic regions. However, investors should be mindful of potential supply chain constraints and the company's reliance on government budgets, which can introduce variability in sales cycles and contract fulfillment.

Axon Enterprise, Inc. demonstrated robust revenue growth in 2020, with net sales increasing by 28.2% to $681.0 million, driven by strong performance in both its TASER and Software & Sensors segments. The company continues its strategic shift towards recurring revenue through its cloud-based Software as a Service (SaaS) offerings, which saw a significant increase in Axon Evidence and cloud services revenue. While the company experienced an operating loss of $14.2 million, largely due to increased stock-based compensation and legal expenses, its gross margin improved to 61.1% from 57.9% in the prior year, indicating growing profitability on its core products and services. Looking ahead, Axon provided a positive outlook for 2021, projecting revenue between $740 million and $780 million, and detailed significant capital expenditures planned for capacity expansion and a new manufacturing facility. The company's strong liquidity position and strategic focus on innovation and recurring revenue streams position it well for continued growth in the public safety technology market.

Axon Enterprise, Inc. (Axon) demonstrated significant revenue growth in its 2019 fiscal year, reaching $530.9 million, a 26.4% increase year-over-year. This growth was primarily driven by its Software and Sensors segment, which saw a 49.3% increase in net sales, largely due to strong performance in its Axon Body cameras and cloud-based Evidence.com services. The TASER segment also experienced growth, up 11.3%, propelled by cartridge sales and the introduction of the new TASER 7 device, though gross margins were compressed due to the new product's higher cost and bundled services. Despite the revenue expansion, the company reported a net income of $0.9 million for the year, a substantial decrease from $29.2 million in the prior year. This decline was largely attributable to significant increases in operating expenses, particularly a substantial rise in stock-based compensation expenses related to CEO and employee performance awards, as well as increased R&D and SG&A spending to support future growth initiatives. The company's backlog also saw a considerable increase, reaching $1.23 billion by year-end, indicating strong future contracted revenue, with a significant portion coming from the Software and Sensors segment.

Axon Enterprise, Inc. (AXON) presented a strong financial performance in its 2018 Form 10-K filing, showcasing significant revenue growth driven by its expanding Software and Sensors segment, which includes body cameras and cloud-based evidence management solutions. The company demonstrated robust top-line expansion, with a notable year-over-year increase in net sales, reflecting growing adoption of its integrated technology solutions by law enforcement agencies. Key financial highlights include substantial growth in bookings for the Software and Sensors segment, indicating a strong future revenue pipeline. While the TASER segment remains a core business, the company's strategic investments in software and cloud services are increasingly contributing to its overall growth and profitability. Axon's focus on recurring revenue models through subscriptions positions it well for sustained expansion, despite acknowledging various risks related to product development, market adoption, competition, and regulatory changes that could impact future performance.

Axon Enterprise, Inc. reported robust top-line growth in 2017, with net sales increasing by 28.2% to $343.8 million. This growth was driven by both its established TASER Weapons segment, which saw a 15.7% increase in net sales, and its rapidly expanding Software and Sensors segment, which experienced a significant 66.6% surge in net sales. The company's strategic focus on its integrated ecosystem of devices, apps, and cloud services for law enforcement and public safety appears to be paying off. The substantial investment in R&D, particularly in AI and new sensor technologies, positions Axon for future innovation. However, investors should note the decline in net income and a decrease in gross margin percentage in 2017, primarily attributed to increased R&D spending and higher costs within the Software and Sensors segment, including data migration expenses and hardware discounting. Additionally, the company is addressing a material weakness in internal controls related to its UK subsidiary, which is being remediated.

Axon Enterprise, Inc. (formerly TASER International, Inc.) reported significant growth in its 2016 fiscal year, with net sales increasing by 35.6% to $268.2 million. This growth was driven by strong performance in both its TASER Weapons segment (up 24.8%) and its rapidly expanding Axon segment (up 84.7%). The company highlighted the increasing adoption of its Axon on-officer cameras and Evidence.com platform as key drivers for the Axon segment's success. Despite robust revenue growth, net income saw a slight decrease to $17.3 million from $19.9 million in the prior year, partly due to increased operating expenses, particularly in Sales, General & Administrative (SG&A) and Research & Development (R&D) to support future growth and new product development. The company also reported a significant increase in its backlog to $384.2 million, indicating strong future revenue potential. Financially, Axon ended the year with $40.7 million in cash and cash equivalents. The company's strategic focus remains on expanding its connected platform, aiming for every officer to carry a TASER device, deploy an Axon camera, and be connected to the Axon network. Investments in AI capabilities through acquisitions signal a commitment to innovation and future growth. Investors should note the company's stated intention not to pay dividends and its ongoing investment in growth initiatives, which will likely continue to drive SG&A and R&D expenses.

Axon Enterprise, Inc. (formerly TASER International, Inc.) reported strong growth in its 2015 fiscal year, driven by significant expansion in its Axon segment (wearable cameras and cloud-based evidence management) and continued strength in its core TASER weapons business. The company's strategic focus on protecting life through its TASER devices and protecting truth with its Axon technologies is yielding positive results, with Axon segment bookings surging by 136.7% year-over-year. This growth is underpinned by increased investment in research and development and a strategic expansion of its sales force, particularly in international markets. Financially, the company demonstrated robust top-line growth, with net sales increasing by 20.3%. The TASER Weapons segment saw a 11.5% increase, largely due to the adoption of newer Smart Weapons like the X26P and X2. The Axon segment was the clear growth engine, with sales jumping 87.8%, fueled by the increasing adoption of on-officer cameras and the Evidence.com platform by law enforcement agencies. Despite rising operating expenses, particularly in R&D and sales/marketing to support growth initiatives, the company maintained net income at $19.9 million for both 2015 and 2014, showcasing improving operational efficiency and gross margins.

Axon Enterprise, Inc. (formerly TASER International, Inc.) reported strong performance in their 2015 10-K filing, with net sales increasing by 19.4% to $164.5 million compared to the previous year. This growth was primarily driven by an 82.6% increase in the AXON segment's net sales, signaling a successful pivot towards and growing adoption of their video and cloud-based evidence management solutions. The TASER Weapons segment also saw a 14.2% increase in net sales, led by the introduction of the TASER X26P smart weapon and customer upgrades to newer models. The company highlights a strategic focus on innovation and market penetration, with significant R&D investment planned for both new products and enhancements to existing platforms, particularly within the AXON segment. International expansion is also a key initiative, with a new international headquarters established in Amsterdam. Management expresses confidence in future growth, supported by increasing bookings for AXON products and EVIDENCE.com, and a robust sales pipeline.

Axon Enterprise, Inc. (formerly TASER International, Inc.) demonstrated robust revenue growth in 2013, driven by strong performance in both its TASER Weapons segment and its burgeoning EVIDENCE.com & Video segment. The company reported a 20.1% increase in net sales, reaching $137.8 million. This growth was primarily fueled by the introduction of new products like the TASER X26P and continued adoption of the AXON body cameras and EVIDENCE.com platform by law enforcement agencies. Financially, the company achieved significant profitability improvements, with net income rising to $18.2 million in 2013, up from $14.7 million in 2012. This performance was supported by improved gross margins and effective management of operating expenses. The company's strategic focus on expanding its video evidence solutions and increasing market penetration, both domestically and internationally, appears to be yielding positive results, positioning it for continued growth in the evolving landscape of law enforcement technology.

Axon Enterprise, Inc. (formerly TASER International, Inc.) reported significant revenue growth in 2012, driven by strong performance in both its Conducted Electrical Weapons (CEW) segment and its burgeoning Video segment. The CEW segment saw an increase in sales, largely due to the popularity of the TASER X2 and the continued upgrade cycle from older models. The Video segment experienced substantial growth, primarily fueled by the adoption of the AXON Flex on-officer recording system and EVIDENCE.COM platform, indicating a successful expansion into new technological areas. The company's strategic focus on innovation, expanding market penetration (both domestically and internationally), and leveraging its installed customer base appears to be yielding positive financial results. Despite some ongoing litigation and the inherent risks in the technology sector, Axon Enterprise demonstrated improved operational efficiency and a return to profitability in 2012, ending the year with a healthy cash position and a clear path for continued growth in its core and emerging product lines.

TASER International, Inc. (now Axon Enterprise, Inc.) filed an amendment to its 2011 10-K report, originally filed on March 13, 2012. This amendment primarily relates to the replacement of Exhibit 32, suggesting a correction or addition to certifications regarding financial reporting. As an accelerated filer, the company's 2011 performance is the focus. While specific financial figures aren't detailed in this excerpt, the filing indicates continued operations and compliance with SEC reporting requirements. Investors should note that this amendment primarily addresses procedural or disclosure adjustments rather than signaling a fundamental change in the company's business or financial health based on this limited information. For investors, the key takeaway is that TASER International was actively engaged in its reporting obligations during the 2011 fiscal year. The fact that it is an accelerated filer means it meets certain market capitalization thresholds and has a history of timely filings, which generally implies a degree of financial maturity and transparency. Further investigation into the specific content of Exhibit 32 and the rest of the original 10-K filing would be necessary to fully assess the company's financial performance and strategic direction.

TASER International, Inc. (now Axon Enterprise, Inc.) reported a net loss of $7.04 million for the fiscal year ended December 31, 2011, a notable decline from the prior year's net loss of $4.38 million. This widened loss was influenced by several factors including a $3.3 million litigation judgment, $3.7 million in excess inventory charges primarily related to the TASER X3 and first-generation AXON products, a $1.4 million impairment charge for the Protector product line, and $2.8 million in losses from the disposal of property and equipment. Despite these challenges, the company saw a slight increase in net sales, reaching $90.0 million, up from $86.9 million in 2010. This growth was driven by higher demand for the newly launched TASER X2 and increased international and federal orders, partially offset by declining sales in older product lines like the TASER X26 and TASER Cam. Financially, the company ended the year with $21.3 million in cash and cash equivalents, a decrease from the previous year, largely due to significant stock repurchases totaling $32.5 million. The company also experienced a decrease in working capital. Looking ahead, TASER International is focused on increasing market penetration in law enforcement, driving sales of its AXON and EVIDENCE.COM platforms, and managing its product lines effectively, including addressing excess inventory. Investors will be watching the company's ability to navigate its ongoing litigation, manage inventory obsolescence, and successfully grow its newer technology offerings.

TASER International, Inc. (now Axon Enterprise, Inc.) in its 2011 10-K filing, highlights its core mission of protecting life and preventing conflict through advanced Electronic Control Devices (ECDs). The company primarily serves law enforcement, military, and corrections markets, emphasizing the safety and effectiveness of its TASER products based on numerous independent studies. A significant strategic initiative involves expanding its technology offerings beyond ECDs into integrated hardware and software solutions for digital evidence management, exemplified by the AXON tactical computer and EVIDENCE.COM platform. Financially, 2010 presented challenges with a 17% decrease in net sales compared to 2009, primarily due to reduced international and federal orders and ongoing budget constraints for domestic law enforcement agencies. Despite the revenue decline, the company focused on cost management, reducing SG&A expenses. The introduction of new product lines like AXON and EVIDENCE.COM contributed to sales, signaling a strategic pivot towards broader technology solutions. The company maintained a strong balance sheet with significant cash reserves and no long-term debt, positioning itself for future growth initiatives.

Axon Enterprise, Inc. (formerly TASER International, Inc.) in its March 15, 2010, 10-K filing, reported total net sales of $104.3 million for the year ended December 31, 2009. This represents a 12.3% increase from the previous year, driven by strong international sales (22% of total) and significant growth in federal and military markets, which offset a decline in domestic municipal spending due to economic constraints. The company's core product, the TASER X26, continued to be a primary revenue driver, along with a substantial contribution from single cartridge sales. Despite the revenue growth, the company experienced a net loss of $1,106 for 2009, a stark contrast to the $3.6 million net income in 2008. This was largely due to a significant increase in research and development (R&D) expenses, which more than doubled to $20 million in 2009, primarily driven by investments in new product development, including the AXON and EVIDENCE.COM digital evidence solution. The company maintains a strong balance sheet with $45.5 million in cash and cash equivalents and no debt, providing financial flexibility for continued investment in innovation and market expansion.

TASER International, Inc. (now Axon Enterprise, Inc.) reported net sales of $92.8 million for the fiscal year ended December 31, 2008, a decrease of 8% from $100.7 million in 2007. This decline was primarily attributed to reduced municipal spending in the U.S. due to the economic downturn, impacting sales of its core TASER X26 product and cartridges. However, the company saw growth in international sales, which represented 18% of total sales in 2008, up from 15% in 2007, with notable advances in the United Kingdom. The company significantly increased its investment in research and development, spending $12.9 million in 2008 compared to $4.4 million in 2007, focusing on new product introductions such as the TASER AXON and EVIDENCE.com platform, expected in 2009. Despite the revenue decrease, gross margins improved to 61.4% in 2008 from 57.1% in 2007 due to cost control and manufacturing efficiencies. The company ended the year with a strong balance sheet, reporting $49.4 million in cash and investments with no debt, providing flexibility for future investments.

Axon Enterprise, Inc. (formerly TASER International, Inc.) reported a strong financial performance for the fiscal year ending December 31, 2007, with net sales increasing by 49% to $100.7 million, up from $67.7 million in 2006. This growth was primarily driven by increased sales of its core TASER X26 product line and related cartridges, alongside a growing installed base of devices among law enforcement agencies. The company also saw a notable contribution from its new consumer product, the TASER C2, launched in mid-2007. The company achieved profitability in 2007, reporting net income of $15.0 million, a significant turnaround from a net loss of $4.1 million in 2006. This profitability was supported by operational efficiencies and successful litigation defense, which minimized disruptions. Axon's strategic focus on expanding market penetration in both domestic and international law enforcement sectors, alongside growing its presence in the private citizen market, positions it for continued growth. The company is also investing heavily in research and development for next-generation technologies and new product introductions, indicating a commitment to innovation and market leadership.

Axon Enterprise, Inc. (formerly TASER International, Inc.) is a global leader in the development and manufacture of electronic control devices (ECDs) primarily for law enforcement, corrections, and personal defense markets. As of their March 15, 2007, 10-K filing, the company's core business revolved around the TASER X26, which had become their best-selling product since its introduction in 2003. The company emphasizes continuous product development, industry-leading training services, and expanding distribution channels, particularly in North America and growing international markets. Financially, 2006 saw a significant rebound in net sales, increasing by 42% to $67.7 million, recovering from a 29% decline in 2005. This recovery is attributed to the resolution of key portions of an SEC investigation that had previously led to postponed purchasing decisions by customers. The company is also actively developing new products, including the TASER Cam, the C2 personal protector for the civilian market, and the XREP wireless projectile technology, aiming to diversify its revenue streams and maintain its technological edge.

Axon Enterprise, Inc. (formerly TASER International, Inc.) is a leading manufacturer of non-lethal self-defense devices, primarily focusing on the law enforcement and military markets, with a growing presence in the consumer sector. The company has experienced significant growth since its early days, transitioning from a focus on private citizen sales to establishing its ADVANCED TASER and TASER X26 product lines as standard equipment for numerous police agencies worldwide. In the fiscal year ending December 31, 2005, the company faced challenges including a decline in net sales by 29% to $47.7 million, largely attributed to negative publicity, ongoing litigation, and lengthened sales cycles. Despite these headwinds, Axon continued to invest in research and development, launching new products like the TASER CAM and advancing technologies such as the XREP cartridge. The company also navigated significant legal proceedings, including a formal SEC investigation that concluded without recommending enforcement action for certain matters. Management is focused on strategies to increase market penetration, innovate product offerings, protect intellectual property, and vigorously defend its brand equity.

TASER International, Inc. (now Axon Enterprise, Inc.) is a rapidly growing company primarily focused on the development and manufacturing of less-lethal self-defense devices, specifically its TASER conducted energy weapons. The company has successfully transitioned from a consumer-focused business to a dominant supplier in the law enforcement and corrections markets, with growing traction in the military and commercial airline sectors. In 2003, the company achieved significant milestones, including the introduction of the TASER X26, the acquisition of its sole competitor (Taser Technologies Inc.), and a substantial increase in net sales (148% growth). The company's strategic focus on expanding its manufacturing and sales infrastructure, alongside robust patent protection, positions it for continued growth. Despite facing ongoing litigation and regulatory scrutiny, management expresses confidence in the company's financial health and future prospects, driven by strong demand from its core markets and expansion into new segments.